Clin Psychopharmacol Neurosci.  2021 Feb;19(1):160-165. 10.9758/cpn.2021.19.1.160.

A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat

Affiliations
  • 1Departments of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea
  • 2Departments of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
  • 3Department of Biomedical and Neuromotor Sciences, Psychiatric Section, University of Bologna, Bologna, Italy
  • 4Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea

Abstract


Objective
We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment-resistant major depressive disorder (TRD) patients in real practice.
Methods
Nine patients were prescribed Neuropharmagen for selection of antidepressants for individual patient and their clinical outcomes were followed.
Results
After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients.
Conclusion
Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients.

Keyword

Treatment; Depressive disorder; Antidepressive agent; Treatment-resistance; Clinical outcome
Full Text Links
  • CPN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error